Abstracts

ASSESSING VACCINE EFFECTIVENESS IN THE REAL WORLD

The test-negative design has been used to estimate influenza vaccine effectiveness (VE) for many years and has more recently been employed for the estimation of COVID-19 VE. In these studies, patients meeting a pre-specified clinical case definition are tested for the disease of interest. Vaccine coverage is compared between those testing positive versus those testing…

POPULATION LEVEL VIRAL SEQUENCING

The COVID-19 pandemic is one of the greatest challenges that humankind has faced in generations. It has already cost more than five million lives globally, sickened over 300 million people around the world, upended countless livelihoods, and caused substantial economic loss. Despite advances in the development and rollout of vaccines as well as in the…

DEEP MUTATIONAL SCANNING TO INTERPRET VIRAL EVOLUTION

Advances in genome sequence have enabled rapid identification of new SARS-CoV-2 variant lineages, but a major challenge is understanding how mutations in these variants will affect anti-viral immunity. Here I describe new high-throughput assays that provide data that can be used to rapidly interpret the consequences of SARS-CoV-2 mutations.

SINGLE-CELL PROTEOMICS

Recently, the throughput of single-cell RNA-sequencing (transcriptomics) and genomics technologies has increased more than a 1000-fold. This increase has powered new analyses: Whereas traditional analysis of bulk tissue averages all differences between the diverse cells comprising such samples, single-cell analysis characterizes each individual cell and thus has enabled the discovery and classification of previously unknown…

LIVER STEATOSIS IN PERSONS LIVING WITH HIV

Liver steatosis is a frequent finding in people living with HIV (PLWH). In the absence of excessive alcohol intake or coinfection with viral hepatitis, metabolic syndrome is the main cause of hepatic steatosis, known as non-alcoholic fatty liver disease (NAFLD). Due to the growing burden of metabolic syndrome in PLWH, NAFLD has become a common…

ANTIRETROVIRALS FOR PREVENTION: FROM ADULTS TO BABIES

Despite decades of progress in decreasing rates of HIV vertical transmission globally, new paediatric infections continue to occur. Postnatal antiretroviral prophylaxis (PNP) remains a critical component of the toolbox available to prevent vertical transmission of HIV. Global guidelines have evolved over the years to better tailor PNP to the changing transmission dynamics influenced by greater…

SPEED DIALING NEONATES TO THE IDEAL POSTNATAL PROPHYLAXIS REGIMEN

Among the multitude of antiretroviral drugs (ARVs) licenced today there are few with dosing and safety information available for neonates, and the majority are liquid formulations. Current neonatal ARVs for postnatal prophylaxis (PNP) typically include ‘older’ drugs such as nevirapine and zidovudine, highlighting the need for more potent and safer ARVs in this population. WHO…

PREPARING FOR THE PLATE OF PREVENTION OPTIONS: HOW CAN WE DELIVER?

HIV prevention has been revolutionized by biomedical advances in pre-exposure prophylaxis (PrEP) which has changed the trajectory of the HIV epidemic in areas with high uptake. PrEP with daily oral tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) was first shown to be effective for HIV prevention in the iPrEx study more than a decade ago, however…

APPLYING LESSONS LEARNED FROM CONTRACEPTION TO PrEP

In this presentation, we will discuss lessons learned from the history of contraception, and apply them to PrEP and specifically the use of longer acting PrEP. We will review best practices in offering PrEP methods in a person-centered manner, with the goal of aligning selected methods with the values and preferences of the patient or…